These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 32677504)

  • 1. Expanding the Role of the Pharmacist: Immunoglobulin Therapy and Disease Management in Neuromuscular Disorders.
    Tichy EM; Prosser B; Doyle D
    J Pharm Pract; 2022 Feb; 35(1):106-119. PubMed ID: 32677504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Subcutaneous immunoglobulin treatment for chronic inflammatory demyelinating polyneuropathy.
    Goyal NA; Karam C; Sheikh KA; Dimachkie MM
    Muscle Nerve; 2021 Sep; 64(3):243-254. PubMed ID: 34260074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of subcutaneous immunoglobulin on quality of life in patients with chronic inflammatory demyelinating polyneuropathy previously treated with intravenous immunoglobulin.
    Vu T; Anthony N; Alsina R; Harvey B; Schleutker A; Farias J; Dang S; Suresh N; Gooch C
    Muscle Nerve; 2021 Sep; 64(3):351-357. PubMed ID: 34076265
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improvement of hemoglobin levels after a switch from intravenous to subcutaneous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy.
    Markvardsen LH; Christiansen I; Jakobsen J
    Transfusion; 2016 Oct; 56(10):2443-2448. PubMed ID: 27401495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subcutaneous Immunoglobulin Therapy for Chronic Inflammatory Demyelinating Polyneuropathy: A Nursing Perspective.
    Watkins JM; Dimachkie MM; Riley P; Murphy E
    J Neurosci Nurs; 2019 Aug; 51(4):198-203. PubMed ID: 31107344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous immunoglobulin as first-line therapy in treatment-naive patients with chronic inflammatory demyelinating polyneuropathy: randomized controlled trial study.
    Markvardsen LH; Sindrup SH; Christiansen I; Olsen NK; Jakobsen J; Andersen H;
    Eur J Neurol; 2017 Feb; 24(2):412-418. PubMed ID: 28000311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Practical Aspects of Transitioning from Intravenous to Subcutaneous Immunoglobulin Therapy in Neuromuscular Disorders.
    Menon D; Sarpong E; Bril V
    Can J Neurol Sci; 2022 Mar; 49(2):161-167. PubMed ID: 33766159
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review.
    Danieli MG; Gelardi C; Pedini V; Moretti R; Gabrielli A; Logullo F
    Autoimmun Rev; 2014 Dec; 13(12):1182-8. PubMed ID: 25172241
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IgPro20, the Polyneuropathy and Treatment with Hizentra
    Berger M; Harbo T; Cornblath DR; Mielke O
    Immunotherapy; 2018 Aug; 10(11):919-933. PubMed ID: 29764262
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Home-based subcutaneous immunoglobulin for chronic inflammatory demyelinating polyneuropathy patients: A Swiss cost-minimization analysis.
    Perraudin C; Bourdin A; Vicino A; Kuntzer T; Bugnon O; Berger J
    PLoS One; 2020; 15(11):e0242630. PubMed ID: 33237959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (The PATH Study): study protocol for a randomized controlled trial.
    van Schaik IN; van Geloven N; Bril V; Hartung HP; Lewis RA; Sobue G; Lawo JP; Mielke O; Cornblath DR; Merkies IS;
    Trials; 2016 Jul; 17(1):345. PubMed ID: 27455854
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of Intravenous Immunoglobulin and Subcutaneous Immunoglobulin in Neurologic Diseases.
    Chen Y; Wang C; Xu F; Ming F; Zhang H
    Clin Ther; 2019 Oct; 41(10):2112-2136. PubMed ID: 31445679
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differentiating characteristics and evaluating intravenous and subcutaneous immunoglobulin.
    Ness S
    Am J Manag Care; 2019 Jun; 25(6 Suppl):S98-S104. PubMed ID: 31318515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravenous and subcutaneous immunoglobulin G replacement therapy.
    Bonilla FA
    Allergy Asthma Proc; 2016 Nov; 37(6):426-431. PubMed ID: 27931296
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcutaneous vs intravenous administration of immunoglobulin in chronic inflammatory demyelinating polyneuropathy: an Italian cost-minimization analysis.
    Lazzaro C; Lopiano L; Cocito D
    Neurol Sci; 2014 Jul; 35(7):1023-34. PubMed ID: 24469345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chronic immunoglobulin maintenance therapy in myasthenia gravis.
    Alcantara M; Sarpong E; Barnett C; Katzberg H; Bril V
    Eur J Neurol; 2021 Feb; 28(2):639-646. PubMed ID: 32964565
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of home-based subcutaneous immunoglobulin G in elderly patients with primary immunodeficiency diseases.
    Stein MR; Koterba A; Rodden L; Berger M
    Postgrad Med; 2011 Sep; 123(5):186-93. PubMed ID: 21904101
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic evaluation of subcutaneous versus intravenous immunoglobulin therapy in chronic inflammatory demyelinating polyneuropathy: a real-life study.
    Piscitelli E; Massa M; De Martino BM; Serio CS; Guglielmi G; Colacicco G; Tuccillo F; Habetswallner F
    Eur J Hosp Pharm; 2021 Nov; 28(Suppl 2):e115-e119. PubMed ID: 33122403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term treatment of Lewis-Sumner syndrome with subcutaneous immunoglobulin infusions.
    Bayas A; Gold R; Naumann M
    J Neurol Sci; 2013 Jan; 324(1-2):53-6. PubMed ID: 23095259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee.
    Tavee J; Brannagan TH; Lenihan MW; Muppidi S; Kellermeyer L; D Donofrio P;
    Muscle Nerve; 2023 Oct; 68(4):356-374. PubMed ID: 37432872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.